Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment

Putting Patients First Best Practices for Neurotrophic Keratitis Diagnosis and Treatment
Media formats available:
Details
Presenters
  • Overview

    This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced.

    Case discussions and audience question-and-answer session were also recorded. 

    Supported by an unrestricted educational grant from Dompé. 

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the stages of neurotrophic keratitis, and how to differentiate it from similar diseases
    • Summarize mechanisms of action of newer treatments and when they should be introduced into treatment regimens for neurotrophic keratitis
    • Identify the relationships between disease characteristics, drug, treatment frequency, visual and anatomic outcomes
    • Recognize the various potential causes of neurotrophic keratitis and when referrals may be necessary
  • Accreditation

    Credit Designation Statement

    Sponsored by

    Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

    This activity, COPE Activity Number 123006, is accredited by COPE for continuing education for optometrists. 
    This course is approved for 1.5 hours of CE. 

    Course # 75785-AS
    Activity  123006

  • Participation Method

    In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

  • Faculty and Disclosures

    Kelly K. Nichols, OD, MPH, PhD, FAAO

    Kelly K. Nichols, OD, MPH, PhD, FAAO

    Program Chair

    Professor and Dean
    University of Alabama at Birmingham School of Optometry
    Birmingham, AL

     

    Scott Hauswirth, OD, FAAO

    Scott Hauswirth, OD, FAAO

    Assistant Professor
    University of Colorado
    Anschutz Medical Campus

    Aurora, CO

     

    Walter O. Whitley, OD, MBA, FAAO

    Walter O. Whitley, OD, MBA, FAAO

    Director of Optometric Services
    Virginia Eye Consultants
    Norfolk, VA

     

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    The following faculty/staff members have the following financial relationships with commercial interests:

    Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bruder, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica, Oyster Point Pharma, Sight Sciences, Tarsis, Thea, and Topivent. Grant/Research: Allergan,  Kala Pharmaceuticals, NIH, and Tear Science. Stock/Shareholder: Acquiom, Alcon Vision, LacriScience, and Tear Film Innovations.

    Scott Hauswirth, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: BioTissue, Eyevance, Glaukos, Horizon, Kala Pharmaceuticals, NuSight Medical, Science Based Health, and Sight Sciences. Grant/Research Support: Claris Biotherapeutics, Dompé, NiCox, Ocular Therapeutix, Oyster Point Pharma, and Sylentis. Speakers List: Kala Pharmaceuticals. Shareholder: Horizon and Oyster Point Pharma.

    Walter O. Whitley, OD, MBA, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocusoft, Oyster Point Pharma, Quidel, Regener-Eyes, RVL Pharmaceuticals, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, TearLab, and Thea Pharmaceuticals. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Bausch + Lomb, Bio-Tissue, Eyevance, Novartis, ScienceBased Health, and Sun Pharmaceutical Industries. Share/Stockholder: Leo Lens Technology.

    The Evolve staff and planners have no financial relationships with commercial interests.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Evolve Medical Education…
but how about a more personalized experience?

Register for free